Tacrolimus, MMF, steroid, and ALG immunotherapy for high immunological risk renal transplant recipients

Transplantation Proceedings

Volumn 33, Issue 1-2, 2001, Pages 1044-1045

  Zaltzman, J ^a,b   McAlister, V ^b   Russell, D ^c   Halloran, P ^d   Landsberg, D ^e   Busque, S ^f   Shoker, A ^g   Boucher, A ^h   Shapiro, J ⁱ   Tchervenkov, J ^j   Peets, J ^b,k  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

^d UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^e ST PAUL S HOSPITAL   (Canada)

^f NOTRE DAME HOSPITAL   (Canada)

^g ROYAL UNIVERSITY HOSPITAL   (Canada)

^h MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

ⁱ VANCOUVER GENERAL HOSPITAL   (Canada)

^j ROYAL VICTORIA HOSPITAL   (Canada)

^k Fujisawa Canada Inc   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; AGED; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL;

EID: 0035083694     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0041-1345(00)02323-X     Document Type: Conference Paper

References (1)

1. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: Transplantation 61:1029, 1996